Sara Hegab
Overview
Explore the profile of Sara Hegab including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoeper M, Rosenkranz S, Badesch D, Humbert M, Langleben D, McConnell J, et al.
Respir Med
. 2024 Dec;
236:107910.
PMID: 39667586
Background: Risk stratification is an essential part of evaluating disease severity in patients with pulmonary arterial hypertension (PAH). This study applied the 4-strata COMPERA 2.0 risk model to the Phase...
2.
Rosenkranz S, Ghofrani H, Hoeper M, Langleben D, Hegab S, Rahner C, et al.
J Heart Lung Transplant
. 2024 Sep;
44(2):135-146.
PMID: 39236972
Background: There is limited evidence to support treatment recommendations in patients with pulmonary arterial hypertension (PAH) and comorbidities. To investigate the impact of riociguat treatment in this patient population, we...
3.
Gorgis S, Mawri S, Dabbagh M, Aurora L, Ali M, Mitchell G, et al.
J Cardiol
. 2022 Jun;
80(5):441-448.
PMID: 35643741
Background: Patients with submassive pulmonary embolism (PE) are vulnerable to sudden deterioration, recurrent PE, and progression to pulmonary hypertension and chronic right ventricular (RV) dysfunction. Previous studies have suggested a...
4.
Ismail R, Hegab S, Kelly B, Franco-Palacios D, Grafton G, Smith Z, et al.
Pulm Circ
. 2021 Nov;
11(4):20458940211037529.
PMID: 34733492
Pulmonary arterial hypertension has evolved from a fatal disease with few treatment options to a chronic condition with improved survival. This improvement is possible through development of effective therapies as...
5.
Maksimowicz-McKinnon K, Zhou J, Hudy J, Hegab S, McKinnon J
J Clin Virol
. 2021 May;
140:104849.
PMID: 34023574
Objective: Subclinical cytomegalovirus (CMV) viremia has been associated with other infections, prolonged hospitalization, and mortality in select immunosuppressed populations. We examined the incidence and outcomes of subclinical CMV viremia in...
6.
Hoffert M, Kerr H, Hegab S, Whitehouse S, Kokas M, MacLean L, et al.
Int J Yoga Therap
. 2020 Nov;
31(1).
PMID: 33157552
Well-being activities may help to counteract physician burnout. Yoga is known to enhance well-being, but there are few studies of yoga as an intervention for physicians in training. This prospective...
7.
Martirosov A, Smith Z, Hencken L, MacDonald N, Griebe K, Fantuz P, et al.
Am J Health Syst Pharm
. 2020 Jun;
77(12):958-965.
PMID: 32495842
Purpose: The purpose of this report is to describe the activities of critical care and ambulatory care pharmacists in a multidisciplinary transitions-of-care (TOC) service for critically ill patients with pulmonary...
8.
Smith Z, Kelly B, Awdish R, Hegab S
J Pharm Pract
. 2018 Mar;
32(5):599-604.
PMID: 29558853
Treprostinil diolamine is the first oral dosage preparation of a prostacyclin analogue for use in treatment naive pulmonary arterial hypertension (PAH). This case series and review of the available literature...
9.
Awdish R, Mendez M, MacDonald N, Yessayan L, Jennings J, Albujoq K, et al.
J Healthc Qual
. 2016 Sep;
39(5):e84-e90.
PMID: 27631708
Parenteral prostacyclin is the most-effective therapy for patients with pulmonary arterial hypertension. Administration is complex, and administration errors are potentially life threatening. Hospital policies to minimize the risk to patients...
10.
Nguyen H, Jaehne A, Jayaprakash N, Semler M, Hegab S, Yataco A, et al.
Crit Care
. 2016 Jul;
20(1):160.
PMID: 27364620
Prior to 2001 there was no standard for early management of severe sepsis and septic shock in the emergency department. In the presence of standard or usual care, the prevailing...